ARTICLE | Clinical News
RDP58: Started Phase II studies
October 29, 2001 8:00 AM UTC
SangStat Medical Corp. (SANG), Fremont, Calif. Product: RDP58 Business: Autoimmune/Inflammation Therapeutic category: Target: TNF-alpha mRNA Description: Peptide inhibitor of TNF-alpha synthesis Ind...